14-3-3Zeta positive expression is associated with a poor prognosis in patients with glioblastoma

Neurosurgery

Volumn 68, Issue 4, 2011, Pages 932-938

  Yang, Xiaoliang ^a   Cao, Weidong ^a   Zhou, Jie ^a   Zhang, Wei ^a,b   Zhang, Xiang ^a   Lin, Wei ^a   Fei, Zhou ^a   Lin, Hong ^a   Wang, Bo ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

14 3 3 zeta; Glioblastoma; Prognostic factor

Indexed keywords

NIMUSTINE; PROTEIN 14 3 3; PROTEIN 14 3 3 ZETA; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOLECULAR DYNAMICS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TUMOR RECURRENCE; BIOSYNTHESIS; BRAIN; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY;

14-3-3 PROTEINS; ADULT; AGED; BRAIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79952897746     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e3182098c30     Document Type: Article

References (38)

1. Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Future Oncol. 2005;1(1):37-50.
2. Dunn J, Baborie A, Alam F, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer. 2009;101(1):124-131.
3. Piperi C, Themistocleous MS, Papavassiliou GA, et al. High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome. Mol Med. 2010;16(1-2):1-9.
4. Ferl RJ, Manak MS, Reyes MF. The 14-3-3s. Genome Biol. 2002;3:S3010.
5. Martin H, Patel Y, Jones D, Howell S, Robinson K, Aitken A. Antibodies against the major brain isoforms of 14-3-3 protein: an antibody specific for the Nacetylated amino-terminus of a protein. FEBS Lett. 1993;336(1):189. (Pubitemid 23362033)
6. Muslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell. 1996;84(6):889-897. (Pubitemid 26106858)
7. Morrison DK. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol. 2009;19(1):16-23.
8. Tzivion G, Gupta VS, Kaplun L, Balan V. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol. 2006;16(3):203-213. (Pubitemid 43810260)
9. van Hemert MJ, Steensma HY, van Heusden GP. 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. Bioessays. 2001;23(10):936-946. (Pubitemid 32972693)
10. Neupane D, Korc M. 14-3-3sigma modulates pancreatic cancer cell survival and invasiveness. Clin Cancer Res. 2008;14:7614-7623.
11. Wen PY, Kesari S. Malignant gliomas in adults. N Engl JMed. 2008;359(5):492-507.
12. Neal CL, Yao J, Yang W, et al. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res. 2009;69(8):3425-3432.
13. Bajpai U, Sharma R, Kausar T, Dattagupta S, Chattopadhayay TK, Ralhan R. Clinical significance of 14-3-3 zeta in human esophageal cancer. Int J Biol Markers. 2008;23(4):231-237.
14. LinM,Morrison CD, Jones S, Mohamed N, Bacher J, Plass C. Copy number gain and oncogenic activity of YWHAZ/14-3-3zeta in head and neck squamous cell carcinoma. Int J Cancer. 2009;125(3):603-611.
15. Matta A, DeSouza LV, Shukla NK, Gupta SD, Ralhan R, Siu KW. Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatographytandem mass spectrometry. J Proteome Res. 2008;7(5):2078-2087.
16. Matta A, Bahadur S, Duggal R, Gupta SD, Ralhan R. Over-expression of 14-3- 3zeta is an early event in oral cancer. BMC Cancer. 2007;7:169.
17. Yang X, Cao W, Lin H, et al. Isoform-specific expression of 14-3-3 proteins in human astrocytoma. J Neurol Sci. 2009;276(1-2):54-59.
18. Fan T, Li R, Todd NW, et al. Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res. 2007;67(16):7901-7906. (Pubitemid 47281386)
19. Gonzales M. The 2000 World Health Organization classification of tumours of the nervous system. J Clin Neurosci. 2001;8(1):1-3. (Pubitemid 32115075)
20. Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Dufour H, Figarella-Branger D. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol. 1998;24(5):381-388. (Pubitemid 28479484)
21. Bodey B, Siegel SE, Kaiser HE. Up-regulation of VEGF expression and related neo-angiogenesis in childhood high-grade gliomas: implications for anti-angiogenic anti-neoplastic therapy. In Vivo. 2006;20(4):511-518. (Pubitemid 44184108)
22. Cao L, Cao W, Zhang W, et al. Identification of 14-3-3 protein isoforms in human astrocytoma by immunohistochemistry. Neurosci Lett. 2008;432(2):94-99.
23. Setoguchi Y, Kato M, Shoji M, et al. Immunocytochemical detection of lung cancer cells with monoclonal antibodies to 14-3-3 proteins. Hum Antibodies Hybridomas. 1995;6(4):137-144.
24. Bortner JD Jr, Das A, Umstead TM, et al. Down-regulation of 14-3-3 isoforms and annexin A5 proteins in lung adenocarcinoma induced by the tobacco-specific nitrosamine NNK in the A/J mouse revealed by proteomic analysis. J Proteome Res. 2009;8(8):4050-4061.
25. Li Z, Zhao J, Du Y, et al. Down-regulation of 14-3-3zeta suppresses anchorageindependent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci U S A. 2008;105(1):162-167.
26. Qi W, Liu X, Qiao D, Martinez JD. Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues. Int J Cancer. 2005;113(3):359-363. (Pubitemid 40038701)
27. Ge F, Lu XP, Zeng HL, et al. Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. J Proteome Res. 2009;8(6):3006-3019.
28. Uhlen M, Bjorling E, Agaton C, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics. 2005;4(12):1920-1932. (Pubitemid 41830186)
29. CaoW, Yang X, Zhou J, et al. Targeting 14-3-3 protein, difopein induces apoptosis of human glioma cells and suppresses tumor growth in mice. Apoptosis. 2010;15(2):230-241.
30. Niemantsverdriet M, Wagner K, Visser M, Backendorf C. Cellular functions of 14-3-3 zeta in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene. 2008;27(9):1315-1319. (Pubitemid 351294692)
31. Porter GW, Khuri FR, Fu H. Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol. 2006;16(3):193-202. (Pubitemid 43796125)
32. Jarpe MB, Widmann C, Knall C, et al. Anti-apoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death. Oncogene. 1998;17(11 reviews):1475-1482. (Pubitemid 28458416)
33. Masters SC, Fu H. 14-3-3 proteins mediate an essential anti-apoptotic signal. J Biol Chem. 2001;276(48):45193-45200.
34. Danes CG, Wyszomierski SL, Lu J, Neal CL, Yang W, Yu D.14-3-3 zeta downregulates p53 in mammary epithelial cells and confers luminal filling. Cancer Res. 2008;68(6):1760-1767. (Pubitemid 351416561)
35. Oksvold MP, Huitfeldt HS, Langdon WY. Identification of 14-3-3zeta as an EGF receptor interacting protein. FEBS Lett. 2004;569(1-3):207-210. (Pubitemid 38844619)
36. Qi W, Martinez JD. Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation. Radiat Res. 2003;160(2):217-223. (Pubitemid 36897502)
37. Frasor J, Chang EC, Komm B, et al. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res. 2006;66(14):7334-7340. (Pubitemid 44197716)
38. Lu J, Guo H, Treekitkarnmongkol W, et al. 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell. 2009;16(3):195-207.